Evidence brief
Semaglutide
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
Yes. Some semaglutide prescription products are FDA-approved for specific uses.
This review covers Ozempic, Rybelsus, Wegovy, and the Wegovy HD strength. Their forms, approved uses, and labels differ.
- How strong is the evidence?
- Established
An official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use we reviewed. It does not mean the product is safe or effective for everyone. - What evidence exists?
- Approved human outcomes
Approved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result. - Sports rules
- No prohibition identified
This review did not find a prohibition in the checked record. This does not clear you to compete.
Reviewed August 30, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Also known as Ozempic · Wegovy · Wegovy HD · Rybelsus · GLP-1 analog
Part of Metabolic peptide medicines
Words used here
- outcome
- what the study measured
- analog
- a changed version made to act like another substance
- compounded
- made for one patient by a pharmacy, or in batches by a permitted outsourcing facility; a compounded drug is not FDA-approved
- randomized
- assigned to study groups by chance
- peptide
- a short chain of amino acids
- receptor
- a protein in a cell that receives a body signal
- agonist
- a substance that activates a receptor
- amino acid
- a small building block that makes peptides and proteins
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
Large studies support the approved uses listed on each product label.
Studies have measured how approved products act in the body and how the body processes them.
Current product labels list known risks, warnings, and when each product should not be used.
High for an authentic approved product. This evidence does not transfer to every compounded version.
02 · Identity
What it is
Semaglutide is a modified peptide. It is the active ingredient in several prescription medicines. The name alone does not tell you the product, form, approved use, or safety rules. FDA approval and study results belong to the exact product and its current label.
Scientific group: GLP-1 receptor agonist. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
Ozempic
May 2026- Formulation
- Injection
- Route
- Injection under the skin
- Indication scope
- Adults with type 2 diabetes for blood-sugar control. The label also covers heart-risk reduction in adults with type 2 diabetes and established heart disease. It covers kidney-risk reduction in adults with type 2 diabetes and chronic kidney disease.
Rybelsus
October 2025- Formulation
- Tablet
- Route
- Tablet by mouth
- Indication scope
- Adults with type 2 diabetes for blood-sugar control. The label also covers heart-risk reduction in adults with type 2 diabetes who are at high risk. It is not approved for weight management.
Wegovy
June 2026- Formulation
- Injection and tablet formulations
- Route
- Injection under the skin or tablet by mouth
- Indication scope
- The injection label covers weight management in defined adults and children age 12 and older. It also covers heart-risk reduction in defined adults. MASH is a liver disease. When used with a reduced-calorie diet and increased physical activity, the injection label covers MASH in adults without cirrhosis who have moderate to advanced liver scarring (F2–F3). The tablet label covers adult weight management and heart-risk reduction.
Wegovy HD
June 2026- Formulation
- 7.2 mg injection strength
- Route
- Injection under the skin
- Indication scope
- The 7.2 mg Wegovy injection strength for the adult weight-management group named in the label.
- Ozempic
- Wegovy
- Wegovy HD
- Rybelsus
- Ozempic: blood-sugar control for adults with type 2 diabetes
- Ozempic: heart-risk reduction for adults with type 2 diabetes and established heart disease
- Ozempic: kidney- and heart-risk reduction for adults with type 2 diabetes and chronic kidney disease
- Rybelsus: blood-sugar control for adults with type 2 diabetes
- Rybelsus: heart-risk reduction for adults with type 2 diabetes who are at high risk
- Wegovy injection: weight management for the adults and children age 12 and older named in the label
- Wegovy tablets: weight management for the adults named in the label
- Wegovy injection and tablets: heart-risk reduction for the adults named in the label
- Wegovy injection, with a reduced-calorie diet and increased physical activity: MASH in adults without cirrhosis who have moderate to advanced liver scarring (F2–F3). FDA granted accelerated approval after improvements in MASH and liver scarring. Continued approval can depend on a later study that confirms benefit.
04 · Research results
What the research shows
FDA-reviewed semaglutide products have approved uses and official labels. Each label says who the product is for, its warnings, side effects, and directions. Read the current label for the exact product. Do not rely on the ingredient name alone.
A shared ingredient name does not make two products the same. Evidence from an approved product does not automatically apply to an unapproved, compounded, counterfeit, or research-labeled product. The name alone does not prove equal quality, safety, or results.
Exact product
Ozempic, Rybelsus, and Wegovy are distinct approved products. Wegovy HD is a higher-dose Wegovy injection strength. Evidence for one product or form does not automatically apply to another.
05 · Claim check
Claims I checked
3 claims checked for this brief.
“Semaglutide is FDA-approved.”
FDA approves a specific product for specific uses. The current Wegovy label lists different forms, groups of people, uses, and limits.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- The exact semaglutide products, forms, people, and uses named in current FDA labels. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Compounded semaglutide is the same as an approved product.”
FDA says compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- Compounded or otherwise unapproved semaglutide products compared with FDA-approved products. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“A result in one population proves the same benefit for everyone.”
A study supports only the people, product form, dose, length, approved use, and result that it tested.
- Evidence used
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- The people, product forms, measured results, and study lengths described in the cited product record. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about Semaglutide
Yes. Some semaglutide prescription products are FDA-approved for specific uses. Approved products identified: Ozempic, Wegovy, Wegovy HD, Rybelsus.
No prohibition identified. No ban was identified in the checked 2026 WADA record. WADA monitors markers of semaglutide in and out of competition. Monitoring is not the same as a ban. Check the current list and your sport's rules. This status is not personal clearance to compete.
FDA-reviewed semaglutide products have approved uses and official labels. Each label says who the product is for, its warnings, side effects, and directions. Read the current label for the exact product. Do not rely on the ingredient name alone.
A shared ingredient name does not make two products the same. Evidence from an approved product does not automatically apply to an unapproved, compounded, counterfeit, or research-labeled product. The name alone does not prove equal quality, safety, or results.
07 · Safety
Safety limits for this record
This guide does not recommend a product, say who can use it, or give dosing instructions. A licensed clinician must use the current label and a person's medical history to make treatment decisions.
No ban was identified in the checked 2026 WADA record. WADA monitors markers of semaglutide in and out of competition. Monitoring is not the same as a ban. Check the current list and your sport's rules.
This review did not find a prohibition in the checked record. This does not clear you to compete.
Reviewed .Check current rules for tested sport ↗Open the governing record ↗08 · Sources
Read the sources
09 · Review history
Review history
Checked current Ozempic, Rybelsus, and Wegovy labels. Added the Wegovy injection use for MASH, kept each form's limits, and checked the 2026 sports monitoring record.
Revalidated the semaglutide approval claim against the current Wegovy label and retained product-, formulation-, population-, and indication-specific scope.
Expanded product, claim, and source provenance fields.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.